Decorin and MRI markers to predict response to anti-VEGF treatment in recurrent glioblastoma
Official title: Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
Funded at University of California Los Angeles · NIH-11305218 · Data updated 2026-11-12
This project looks at whether a protein called decorin and a type of MRI (diffusion MRI) can help predict which people with recurrent glioblastoma will benefit from anti-VEGF therapy like bevacizumab.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $591,984 |
| NIH project number | 5R01CA270027-05 |
| Project ID | NIH-11305218 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with recurrent glioblastoma who are being considered for anti-VEGF therapy and can undergo diffusion MRI and provide tumor tissue or blood samples.
✕Less likely to help
People with newly diagnosed glioblastoma, those not receiving anti-VEGF therapy, or those unable to have MRI or provide samples may not benefit from this work.
What this research studies
This project combines diffusion MRI scans and measurements of the protein decorin from tumor tissue or blood in people with recurrent glioblastoma. Researchers will compare MRI apparent diffusion coefficient (ADC) patterns and decorin levels with how patients do after anti-VEGF treatment such as bevacizumab. The work will use existing patient data and prospectively collected imaging and samples to link these markers with survival and treatment response. The goal is to develop markers that help guide treatment choices and identify patients for future trials.
Why it matters
Potential benefit: If successful, this could help doctors identify which patients are likely to benefit from anti-VEGF therapy and avoid ineffective treatments.
How similar studies have gone: Previous analyses of over 400 patients across multiple trials suggest diffusion MRI (high ADC) predicts better response to anti-VEGF therapy, while using decorin as an added biomarker is a newer approach with less prior testing.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Ellingson, Benjamin M. — University of California Los Angeles
- Study coordinator: Ellingson, Benjamin M.
Related research
Other NIH-funded projects on the same topics.
-
Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Targeting Fatty Acid Metabolism to Fight Brain Cancer (GBM)
A new treatment approach uses a repurposed drug to cut off the energy supply of glioblastoma tumors in the brain.
-
Giving immune checkpoint therapy before surgery for recurrent glioblastoma
This research gives an immune checkpoint drug before surgery to people with recurrent glioblastoma to help the immune system attack the tumor.
-
Using immune therapy before surgery for recurrent glioblastoma
This study is looking at how giving a special immune therapy before surgery can help patients with recurrent glioblastoma fight their tumors better, and it will compare the results to the usual treatments given after surgery.
-
Investigating how decorin and MRI can improve treatment for recurrent glioblastoma
This study is looking at how a special protein and MRI scans can help doctors figure out which patients with recurring glioblastoma might benefit the most from a treatment that blocks blood vessel growth in tumors, with the goal of improving outcomes for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.